Last reviewed · How we verify
interruption of Glivec®
Glivec is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR.
Glivec is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR. Used for Chronic myeloid leukemia, Acute lymphoblastic leukemia.
At a glance
| Generic name | interruption of Glivec® |
|---|---|
| Sponsor | Centre Leon Berard |
| Drug class | tyrosine kinase inhibitor |
| Target | BCR-ABL, c-KIT, PDGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the ATP-binding site of these kinases, thereby inhibiting their activity and preventing the proliferation of cancer cells. This leads to a reduction in tumor size and an improvement in symptoms.
Approved indications
- Chronic myeloid leukemia
- Acute lymphoblastic leukemia
Common side effects
- Myelosuppression
- Nausea
- Diarrhea
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- interruption of Glivec® CI brief — competitive landscape report
- interruption of Glivec® updates RSS · CI watch RSS
- Centre Leon Berard portfolio CI